- Home
- MTA vs GERN Comparison
MTA vs GERN Comparison
Compare MTA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- GERN
- Stock Information
- Founded
- MTA 1983
- GERN 1990
- Country
- MTA Canada
- GERN United States
- Employees
- MTA N/A
- GERN N/A
- Industry
- MTA
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- MTA
- GERN Health Care
- Exchange
- MTA Nasdaq
- GERN Nasdaq
- Market Cap
- MTA 638.7M
- GERN 740.5M
- IPO Year
- MTA N/A
- GERN 1996
- Fundamental
- Price
- MTA $7.24
- GERN $1.20
- Analyst Decision
- MTA Hold
- GERN Buy
- Analyst Count
- MTA 1
- GERN 7
- Target Price
- MTA $7.50
- GERN $3.00
- AVG Volume (30 Days)
- MTA 499.9K
- GERN 9.0M
- Earning Date
- MTA 11-13-2025
- GERN 11-05-2025
- Dividend Yield
- MTA N/A
- GERN N/A
- EPS Growth
- MTA N/A
- GERN N/A
- EPS
- MTA N/A
- GERN N/A
- Revenue
- MTA $10,546,000.00
- GERN $183,403,000.00
- Revenue This Year
- MTA $117.14
- GERN $166.20
- Revenue Next Year
- MTA $69.62
- GERN $55.83
- P/E Ratio
- MTA N/A
- GERN N/A
- Revenue Growth
- MTA 108.91
- GERN 522.13
- 52 Week Low
- MTA $2.45
- GERN $1.04
- 52 Week High
- MTA $7.73
- GERN $4.21
- Technical
- Relative Strength Index (RSI)
- MTA 59.50
- GERN 52.29
- Support Level
- MTA $6.42
- GERN $1.05
- Resistance Level
- MTA $7.09
- GERN $1.28
- Average True Range (ATR)
- MTA 0.33
- GERN 0.07
- MACD
- MTA 0.02
- GERN 0.01
- Stochastic Oscillator
- MTA 93.69
- GERN 66.67
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.